Dexcom Inc

DXCM has formed a Blow-Off Top at the July peak, marking the terminal phase of its previous advance. Medium-term bias is bearish, reflecting a shift into Stage 3 distribution. Price is extended above rising EMAs and recently rejected at resistance with a long upper wick, so selling now carries exhaustion risk. We will trim into any rally into the 74.7–76.6 resistance zone, using rejection at resistance as our interaction method.

• ↑Dexcom G7 15-day system approved in Canada expands user adoption.
• ↑Q1 2026 revenue $1.19B (+15% YoY); net income $216M (+75%).
• ↓Valuation appears stretched with weak earnings-yield and overvalued book-to-price factors.